SCHEMBL7149256

SCHEMBL7149256

COc1cccc(NS(=O)(=O)CSc2nc3ccc(OC)cc3s2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
MEN1 O00255 4/20 0.54
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
KMT2A Q03164 4/20 0.54
ALDH1A1 P00352 1/20 0.54
GAA P10253 1/20 0.54
HTT P42858 1/20 0.54
PDK1 Q15118 1/20 0.52
LMNA P02545 5/20 0.50
TP53 P04637 2/20 0.50
THRB P10828 2/20 0.49
POLB P06746 2/20 0.47
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
CTSL P07711 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7149774 0.93 MAPT (0.50) MAPTSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL7144781 0.92 MAPT (0.52) MAPTSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL7151274 0.90 PDK1 (0.55) MAPTSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL7151273 0.90 MAPT (0.52) MAPTSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL7148790 0.88 MAPT (0.50) MAPTSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL7149250 0.87 PDK1 (0.52) MAPTSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL7152202 0.87 MAPT (0.49) MAPTSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL7151080 0.87 LMNA (0.49) MAPTSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL7153200 0.85 MAPT (0.55) MAPTSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL7149643 0.83 PDK1 (0.50) MAPTSMN1; SMN2MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 MAPT 3839/4885SMN1; SMN2 3295/4885MEN1 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.